Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.54 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.54 |
| ▸ | BRAF | P15056 | 14/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.53 |
| ▸ | MEN1 | O00255 | 3/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 3/20 | 0.51 |
| ▸ | HTT | P42858 | 2/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29877332 | 1.00 | MAPT (0.54) | MAPTMCL1BRAFCYP2C9MEN1 | |
| SCHEMBL1697857 | 0.88 | MAPT (0.64) | MAPTBRAFCYP2C9MEN1KMT2A | |
| SCHEMBL29877649 | 0.88 | MAPT (0.64) | MAPTBRAFCYP2C9MEN1KMT2A | |
| SCHEMBL1697928 | 0.88 | BRAF (0.52) | MAPTBRAFCYP2C9MEN1KMT2A | |
| SCHEMBL1698163 | 0.85 | BRAF (0.50) | BRAFCYP2C9KMT2AMAPK1RAB9A | |
| SCHEMBL811365 | 0.85 | MAPT (0.60) | MAPTMCL1MEN1KMT2AMAPK1 | |
| SCHEMBL5004766 | 0.83 | BRAF (0.59) | BRAFCYP2C9 | |
| SCHEMBL2858498 | 0.83 | MEN1 (0.67) | MAPTBRAFCYP2C9MEN1KMT2A | |
| SCHEMBL1455951 | 0.80 | MAPT (0.63) | MAPTMCL1MEN1KMT2AMAPK1 | |
| SCHEMBL1454512 | 0.79 | MAPT (0.59) | MAPTMCL1MEN1KMT2ARAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080207616-A1 | Quinoxalines as B Baf Inhhibitors | ASTRAZENECA AB (SE) | 2008-08-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080207616-A1 | Quinoxalines as B Baf Inhhibitors | BRAF, NRAS, ARAF | MAPT 4559/4885MCL1 77/4885BRAF 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.